Track topics on Twitter Track topics that are important to you
Ferrer Grupo offers products of a high scientific standard, according to client needs, together with health training programmes which provide up-to-date information on the constant improvements in the fields of medicine and pharmacology, and maintain direct contact with health professionals, patients and the general public.
Edifici L'illaDiagonal, 549 5a planta
Phone: 34 93 600 37 00
Fax: 34 93 490 70 78
Alexza Pharmaceuticals will be acquired for £0.62 ($0.90) per share in cash by Ferrer Pharma, a wholly-owned subsidiary of Grupo Ferrer Internacional (Ferrer)
Edison Investment Research - Pharmaceutical & Healthcare - Alexza Pharmaceuticals: Alexza disclosed on 26 February that it had entered into a non-binding letter of intent (LOI) from Ferrer on 15 Febru...
* Under agreement, Ferrer Pharma , a wholly-owned subsidiary of Ferrer, will acquire co for $0.90 per share in cash.
NewsAlexza Pharmaceuticals confirms entering into a non-binding letter of intent with Grupo Ferrer Internacional, S.A. with respect to Ferrer's proposed acquisition of all outstanding common shares ...
Alexza Pharmaceuticals said today it has agreed to be acquired by Grupo Ferrer Internacional for up to nearly $55 million, in a deal that adds Alexza’s marketed drug Adasuve® (Staccato lox...
Per a non-binding letter of intent, private Spanish company Grupo Ferrer Internacional SA aims to acquire all shares of public US biotech Alexza Pharmaceuticals Inc. (CNS therapeutics) that it doesn't...
Grupo Ferrer Internacional will acquire Alexza Pharmaceuticals for around $2m, adding the Staccato aerosol system to its drug delivery offerings.
Edison Investment Research - Pharmaceutical & Healthcare - Alexza Pharmaceuticals: Ferrer entered into a definitive agreement with Alexza, whereby Ferrer will acquire the company for $0.90 per share i...
During the last decade, there has been a tremendous effort to develop different cardiovascular polypills in response to the upsurge in global cardiovascular disease worldwide. The pharmacological deve...
The aim of this study was to predict the improvement of the marginal reflex distance (MRD1) in each blepharoptosis surgery.In PubMed and Scopus, the search terms 1. (blepharoptosis) AND 2. (surgery) A...
"Echocardiographic abnormalities in patients with COPD at their first hospital admission." Xavier Freixa, Karina Portillo, Carles Paré, Judith Garcia-Aymerich, Federico P. Gomez, Marta Benet, Josep Roca, Eva Farrero, Jaume Ferrer, Carlos Fernandez-Palomeque, Josep M. Antó and Joan Albert Barberà, on behalf of the PAC-COPD Study Investigators. Eur Respir J 2013; 41: 784-791.
Three new species of Macrelmis Motschulsky, 1859 are described and illustrated based on adult males from Rio de Janeiro, Minas Gerais and São Paulo states (southeastern Brazil). A new species groups ...
The aim of this study was to investigate the antioxidant properties of udenafil citrate (1.4 mg kg(-1) -2.8 mg kg(-1) ), dexmedetomidine 25 μg kg(-1) and piracetam 200 mg kg(-1) administered ...
The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.
The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...
Object: To explore the mechanism of the electro-acupuncture (EA) induced sedation effect in general anaesthesia through investigating the role of the Benzodiazepines-GABA system. Method: ...
The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...
Assessing OCD before and after group therapy
Ferrer Grupo offers products of a high scientific standard, according to client needs, together with health training programmes which provide up-to-date information on the constant improvements in the...
Ferrer Freeman & Company, LLC, is a private equity firm located in Greenwich, CT focuses exclusively on growth capital investments in the healthcare industry. Since its founding i...
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for ...
W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...
PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...
We have published hundreds of Ferrer Group Inc. news stories on BioPortfolio along with dozens of Ferrer Group Inc. Clinical Trials and PubMed Articles about Ferrer Group Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ferrer Group Inc. Companies in our database. You can also find out about relevant Ferrer Group Inc. Drugs and Medications on this site too.
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...